Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Cash & Equivalents (2022 - 2025)

Prokidney (PROK) has disclosed Cash & Equivalents for 4 consecutive years, with $108.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 9.5% to $108.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $108.5 million through Dec 2025, up 9.5% year-over-year, with the annual reading at $108.5 million for FY2025, 9.5% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $108.5 million at Prokidney, up from $95.3 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $506.3 million in Q3 2022, with the low at $60.6 million in Q4 2023.
  • Average Cash & Equivalents over 4 years is $189.8 million, with a median of $108.3 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents crashed 87.63% in 2023, then soared 63.43% in 2024.
  • Over 4 years, Cash & Equivalents stood at $490.3 million in 2022, then plummeted by 87.63% to $60.6 million in 2023, then skyrocketed by 63.43% to $99.1 million in 2024, then grew by 9.5% to $108.5 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $108.5 million, $95.3 million, and $84.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.